Becton, Dickinson and Company $BDX Shares Sold by Webster Bank N. A.

Key Points

• Webster Bank N. A. reduced its stake in Becton, Dickinson and Company by 66.2% during the second quarter, holding 2,423 shares worth approximately $417,000.
• Becton, Dickinson and Company reported earnings of $3.68 per share for the recent quarter, exceeding expectations, with revenue up 10.4% year-over-year.
• The firm announced a quarterly dividend of $1.04, with an annualized yield of 2.2%, reflecting a payout ratio of 74.82%.

Webster Bank N. A. cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 66.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,423 shares of the medical instruments supplier's stock after selling 4,740 shares during the period. Webster Bank N. A.'s holdings in Becton, Dickinson and Company were worth $417,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BDX. Brighton Jones LLC lifted its position in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after purchasing an additional 27,581 shares during the period. FORA Capital LLC acquired a new stake in Becton, Dickinson and Company in the first quarter worth approximately $3,458,000. Foster Victor Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company in the first quarter worth approximately $6,406,000. Finally, GAMMA Investing LLC lifted its position in Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock worth $744,000 after purchasing an additional 748 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.5%

Shares of NYSE:BDX opened at $185.90 on Tuesday. The stock has a market capitalization of $53.29 billion, a PE ratio of 33.44, a P/E/G ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a fifty day moving average price of $186.72 and a 200 day moving average price of $190.98. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the company posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of the company's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,965 shares of company stock valued at $551,536 over the last quarter. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on BDX shares. Morgan Stanley upped their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Barclays dropped their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.